Ovarian Cancer Clinical Trials in Austin

Showing 81-97 of 97 trials

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

NCT00281632

This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.

Peritoneal CancerOvarian CancerNeoplasms, Ovarian+1 more

GlaxoSmithKline35 participantsStarted Mar 2006

Atlanta, Georgia, United States • Austin, Texas, United States • Bedford, Texas, United States +7 more locations

TERMINATEDPHASE3< 1 mile

Clinical Trial for Ovarian Cancer (OvaRex®)

NCT00050375

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Ovarian Cancer

Unither Pharmaceuticals354 participantsStarted Dec 2002

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +59 more locations

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Clinical Trial for Ovarian Cancer (OvaRex®)

Ovarian Cancer Trials in Other Cities

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Ovarian Cancer Vaccine for Patients in Remission

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Other Conditions in Austin